Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001415889-25-005113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-21 | 2025-02-19 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale | $4.41 | -4,326 | 220.1K | -2% | -$19.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-19 | S | D | 4,326 | $4.41 | 220,119 | D | — | — | (F2) Includes 136,562 RSUs. |